MUC4 expressing pancreatic cancer cells exhibit greater resistance to gemcitabine than MUC4 negative cells, through activation of anti-apoptotic pathways, thereby promoting cell survival [79]. This evidence concerns the gene MUC4 and familial pancreatic carcinoma.